Some sketchy clues are surfacing concerning the nature of the
search for a new president for the $3 billion California stem cell
agency.
They popped up in an RFP for help from an executive search firm to
find candidates to replace Alan Trounson, who is resigning to return
to his home country of Australia. (He is scheduled to be in Chile this week.)
The RFP contained a “draft” of a description of the job of the
new CEO. It said that the salary could range as high as $548,788
annually with a benefit package that appeared to be negotiable. That
could be important if the new president might come from out-of-state
to California's sky high home prices.
According to the description, the new president should be a
“well-recognized leader.” Notably the description did not specify
that the individual must be a scientist but said the person should
have “scientific credibility.” The individual must have both
“unassailable integrity” and “ a solid reputation for ethics
and integrity and be sufficiently self-possessed to not be perturbed
by criticism or controversy.” The agency also appeared to exclude
candidates from overseas, limiting the search to the United States.
The RFP indicated that the job description might be changed as the
governing board works through its selection process. The board's
Presidential Search Subcommittee will hold its first meeting this Friday, some of which is public.
The RFP also said that “outside time limit” for selection of
the president is six months from the award of the contract, scheduled
for Dec. 16. Responses to the RFP must be submitted no later than
Nov. 26. No price tag was put on the search contract although the
last one in 2009 was budgeted for $100,000. And it did not come up
with Trounson, the person who snagged the job that time around.
Our take? The agency faces several critical decisions in the next
few months, including action on a plan to finance its future since it
runs out of money for new grants in 2017. Also on the table are
decisions on the handful of research projects that it expects to back more strongly in hopes of more successfully promoting
commercialization of stem cell therapies. That is not to mention the
ambitious proposed $70 million Alpha stem cell clinic effort. Assuming six
months to hire a new president and another six months before the
person is actually in place, the new CEO could be well behind the
curve by the time he or she is on the job. While it is three years or
so before money runs out, the reality is that the agency must move
with considerable dispatch to cement its continued existence.
Building support and positive recognition is a long-term project, and
right now the stem cell agency is little known outside of scientific
circles, which are small indeed. Producing something akin to a cure
is also crucial in winning support from lawmakers, the public or the
private sector.
The nine-year-old agency has had only two presidents, not counting
one interim CEO. Selection of those presidents was marked by
considerable difficulties, including divergent views of the CEO role
among board members. However, the need for speed and continuity at
the agency may smooth over some of those rough spots in this latest
presidential search.
With more than 3.0 million page views and more than 5,000 items, this blog provides news and commentary on public policy, business and economic issues related to the $3 billion California stem cell agency. David Jensen, a retired California newsman, has published this blog since January 2005. His email address is djensen@californiastemcellreport.com.
Monday, November 11, 2013
Sunday, November 10, 2013
Prowess and Conflicts: A Media Primer on the California Stem Cell Agency
The major daily newspaper in the San Diego area, a hotbed of
biotech and stem cell research, is carrying a lengthy piece on the
status of the California stem cell agency.
The article was written by Bradley Fikes. The headline on the article on the Web site of the San Diego UT said,
Fikes also mentioned the longstanding conflict of interest issues at the agency. The California Stem Cell Report has calculated that about 90 percent of the $1.9 billion awarded by the agency's directors has gone to institutions linked to directors. Fikes wrote,
The article was written by Bradley Fikes. The headline on the article on the Web site of the San Diego UT said,
“Stem cell program is making progress.”Fikes said that “CIRM’s scientific prowess is generally acknowledged by its critics” and cited nine early stage clinical trials that have received some agency funding for research along the way. But he also wrote,
“It’s clear that treatments haven’t come as fast as optimists had hoped. No therapies funded by the agency have been approved.”He continued with a mention of the 2004 ballot campaign that created the agency, an effort that was criticized for hyping stem cell research. Fikes wrote,
“As it turned out, researchers simply didn’t know enough about stem cells to rush them into clinical trials. So the agency, the California Institute for Regenerative Medicine, or CIRM, stuck to the basics.”The piece is something of a primer on the agency, which is appropriate for the general readership of the newspaper. Even with San Diego's strong stem cell presence, the overwhelming majority of readers of the paper are unlikely to know much about the research or the agency.
Fikes also mentioned the longstanding conflict of interest issues at the agency. The California Stem Cell Report has calculated that about 90 percent of the $1.9 billion awarded by the agency's directors has gone to institutions linked to directors. Fikes wrote,
“'From the very beginning, it was clear that CIRM fundamentally was composed of people who decided to give out the money who, by and large, represented the people who receiving the money,' said John Simpson of Santa Monica-based Consumer Watchdog.”As of this writing, no readers of the newspaper had filed comments on the article.
Friday, November 08, 2013
The Search for a New California Stem Cell Agency CEO
The governing board of the $3 billion California stem cell agency
faces a critical leadership challenge in the next few months as it
attempts to find a new president for the nine-year-old organization.
It is a challenge in at least two ways. One is the more or less straight-forward process of finding candidates to replace Alan Trounson, who is leaving to return to his family in Australia. The second is whether the governing board can move quickly and unite on the needed attributes for the next president.
That may sound simpler than it is. But the 29-member board is large and unwieldy. A nine-member board, for instance, would be able to make decisions much more quickly. In the last presidential search, the board had difficulty in coming together on the qualities for a new CEO. Today the choice would seem to be between a star or semi-star researcher or a knowledgeable person who can synthesize the choices and make the stem cell train run on time.
The agency also is confronting an unusual financial situation – at least in terms of recruitment – that is likely to make it more difficult to find top level candidates. The agency will be all but out of business in 2017 unless it can secure additional funding. Money for new grants will run out that year. Top candidates for the presidency may find that possibility unappealing. The situation will also require a president who understands fund-raising, both public and private, and can successfully navigate California political and governmental byways. The agency is currently involved in developing a plan for its future finances, including possibly some sort of public-private combination.
Another issue that is likely to complicate recruitment is the troublesome dual-executive arrangement at the agency in which the chairman of the organization and president have overlapping responsibilities. Some candidates may not be willing to step into such a situation, which is legally dictated by Prop. 71, the ballot measure that created the agency, and which is politically impossible to change in the next couple of years.
The new president will also have to be a person who can help retain staff at the San Francisco-based agency, which has only slightly more than 50 employees. Now is not the time to be losing key personnel, but given the funding situation, some may be tempted to take advantage of appealing opportunities elsewhere.
One straight-forward way to deal with the vacancy is to look internally. Such a course has several advantages: It would require no learning curve and would demonstrate a commitment to existing employees. But foremost, it could be done quickly and ensure stability. Another possibility is to find a candidate – retired or in the late stages of his or her career – who would be willing to step in for a few years to keep the agency on course during this critical period. It could be appealing to the right person, given the unusual nature of the agency and the challenges that it faces.
Trounson is remaining in place at least during the initial stages of the presidential search. But he is already a lame duck and will unavoidably become more of one as time passes. His focus will naturally and justifiably shift to his family concerns and his return to Australia. That will inevitably create managerial slowdown and procrastination at a time when speed is necessary – not only for finding new funding sources but for making important strategic decisions on the most promising avenues to pursue to commercialize stem cell research.
The board's Presidential Search Subcommittee meets one week from today to begin its work. A public session will precede a closed-door personnel meeting. Some documents from previous presidential searches are available on the CIRM Web site via the agenda for the meeting. The public can take part in the public portion, which is likely to be quite brief, at locations in San Francisco, Los Angeles, Irvine and La Jolla. The specific locations can be found on the agenda.
Stakeholders in the stem cell community are welcome to weigh with comments or suggestions at the session or by sending them to info@cirm.ca.gov.
The members of the subcommittee, in alphabetical order, are Sue Bryant, interim provost at UC Irvine; Anne-Marie Duliege, chief medical officer at Affymax; Sam Hawgood, dean of the UC San Francisco medical school; Steve Juelsgaard, former executive vice president of Genentech; Sherry Lansing, former chair of the UC regents and Hollywood studio CEO, Jeff Sheehy, a patient advocate board member and communications manager at UC San Francisco; Jonathan Thomas, chairman of the agency board and a Los Angeles bond financier; Art Torres, vice chairman of the agency and former head of the state Democratic party, and Kristiina Vuori, president of the Sanford-Burnham Institute.
It is a challenge in at least two ways. One is the more or less straight-forward process of finding candidates to replace Alan Trounson, who is leaving to return to his family in Australia. The second is whether the governing board can move quickly and unite on the needed attributes for the next president.
That may sound simpler than it is. But the 29-member board is large and unwieldy. A nine-member board, for instance, would be able to make decisions much more quickly. In the last presidential search, the board had difficulty in coming together on the qualities for a new CEO. Today the choice would seem to be between a star or semi-star researcher or a knowledgeable person who can synthesize the choices and make the stem cell train run on time.
The agency also is confronting an unusual financial situation – at least in terms of recruitment – that is likely to make it more difficult to find top level candidates. The agency will be all but out of business in 2017 unless it can secure additional funding. Money for new grants will run out that year. Top candidates for the presidency may find that possibility unappealing. The situation will also require a president who understands fund-raising, both public and private, and can successfully navigate California political and governmental byways. The agency is currently involved in developing a plan for its future finances, including possibly some sort of public-private combination.
Another issue that is likely to complicate recruitment is the troublesome dual-executive arrangement at the agency in which the chairman of the organization and president have overlapping responsibilities. Some candidates may not be willing to step into such a situation, which is legally dictated by Prop. 71, the ballot measure that created the agency, and which is politically impossible to change in the next couple of years.
The new president will also have to be a person who can help retain staff at the San Francisco-based agency, which has only slightly more than 50 employees. Now is not the time to be losing key personnel, but given the funding situation, some may be tempted to take advantage of appealing opportunities elsewhere.
One straight-forward way to deal with the vacancy is to look internally. Such a course has several advantages: It would require no learning curve and would demonstrate a commitment to existing employees. But foremost, it could be done quickly and ensure stability. Another possibility is to find a candidate – retired or in the late stages of his or her career – who would be willing to step in for a few years to keep the agency on course during this critical period. It could be appealing to the right person, given the unusual nature of the agency and the challenges that it faces.
Trounson is remaining in place at least during the initial stages of the presidential search. But he is already a lame duck and will unavoidably become more of one as time passes. His focus will naturally and justifiably shift to his family concerns and his return to Australia. That will inevitably create managerial slowdown and procrastination at a time when speed is necessary – not only for finding new funding sources but for making important strategic decisions on the most promising avenues to pursue to commercialize stem cell research.
The board's Presidential Search Subcommittee meets one week from today to begin its work. A public session will precede a closed-door personnel meeting. Some documents from previous presidential searches are available on the CIRM Web site via the agenda for the meeting. The public can take part in the public portion, which is likely to be quite brief, at locations in San Francisco, Los Angeles, Irvine and La Jolla. The specific locations can be found on the agenda.
Stakeholders in the stem cell community are welcome to weigh with comments or suggestions at the session or by sending them to info@cirm.ca.gov.
The members of the subcommittee, in alphabetical order, are Sue Bryant, interim provost at UC Irvine; Anne-Marie Duliege, chief medical officer at Affymax; Sam Hawgood, dean of the UC San Francisco medical school; Steve Juelsgaard, former executive vice president of Genentech; Sherry Lansing, former chair of the UC regents and Hollywood studio CEO, Jeff Sheehy, a patient advocate board member and communications manager at UC San Francisco; Jonathan Thomas, chairman of the agency board and a Los Angeles bond financier; Art Torres, vice chairman of the agency and former head of the state Democratic party, and Kristiina Vuori, president of the Sanford-Burnham Institute.
Wednesday, November 06, 2013
Tracking the California Stem Cell Agency: The Calendar for 2014
The coming year will be a big one for the California stem cell
agency and all the many researchers, institutions and companies who
have millions of dollars tied to it.
The key decisions involve hiring a new president and creating a new course to a secure financial future – not to mention handing out hundreds of millions of more dollars.
Tracking the doings of the San Francisco enterprise can best be done through attendance at its day-long board meetings, where the public and interested parties have an opportunity to talk board members and the agency staff.
CIRM recently posted its schedule for seven meetings during 2014, ranging from San Diego to the San Francisco Bay area. All are currently one-day sessions with the exception of December 2014, which will involve two days. You can find the schedule here for guidance in planning your 2014 calendar. Keep in mind that meeting dates sometimes change but those changes are not always reflected on this particular calendar.
The key decisions involve hiring a new president and creating a new course to a secure financial future – not to mention handing out hundreds of millions of more dollars.
Tracking the doings of the San Francisco enterprise can best be done through attendance at its day-long board meetings, where the public and interested parties have an opportunity to talk board members and the agency staff.
CIRM recently posted its schedule for seven meetings during 2014, ranging from San Diego to the San Francisco Bay area. All are currently one-day sessions with the exception of December 2014, which will involve two days. You can find the schedule here for guidance in planning your 2014 calendar. Keep in mind that meeting dates sometimes change but those changes are not always reflected on this particular calendar.
Tuesday, November 05, 2013
Denny Sanford Donates $100 Million for Stem Cell Research at UC San Diego
Denny Sanford, UC San Diego photo |
He is Denny Sanford, a 77-year-old billionaire who made his fortune in the credit card business. Sanford is donating the money to UC San Diego. In a press release from the university, he said,
“I believe we’re on the cusp of turning years of hard-earned knowledge into actual treatments for real people in need. I want this gift to push that reality faster and farther.”The gift is not Sanford's first to stem cell research in the San Diego area. He gave $30 million to Sanford Consortium for Regenerative Medicine in 2008.
The announcement of the $100 million donation is the sort of news that excites the stem cell field globally but especially in California, where the state is funding stem cell research to the tune of $3 billion. The news helps generate optimism about the stem cell field and can create an environment that could attract more philanthropy and business investments.
That is not a small matter for the state's stem cell agency, which will run out of cash for new grants in 2017. Next month, directors of the agency are scheduled to take their first look at a proposed strategic roadmap for future funding, which may well involve a combination of public and private funding.
According to Gary Robbins of the San Diego UT, Sanford's latest gift is part of a $275 million stem cell effort at UC San Diego. Robbins said it will allow the university to hire 20 to 25 scientists, many of whom will be seeking stem cell agency grants, and also help to support recruitment of patients for clinical trials. UC San Diego has already received $138 million in 61 awards from the stem cell agency, ranking fourth among institutional recipients.
The UC San Diego press release yesterday also quoted David Brenner, vice chancellor for health services at the campus and a member of the California stem cell agency governing board, as saying,
“We are the only academic medical institution in the region with the scientists, physicians, facilities and clinical delivery system to bring the promise of stem cell therapies to fruition. No place in the world has a better chance of success.”Larry Goldstein, currently director of the UC San Diego stem cell program, will head the new Sanford Stem Cell Clinical Center at the school.
The news coverage on the gift, which included stories in the Los Angeles Times and other publications, contained a number of mentions of the state stem cell agency, a plus for the enterprise, which is working hard to raise its public visibility.
Sanford's latest gift is not his largest. He gave $400 million to Sanford Health, a diabetes research center in South Dakota in 2009. He has donated more than $1 billion altogether and intends to give away all his money by the time he dies. He likes to say, “Aspire to inspire before you expire.”
Sanford lives in Sioux Falls but has a home in the San Diego area, where he has long been active in the community as well as in support of Prop. 71, the measure that created the state stem cell agency in 2004.
Sanford is also a sailor, a particular point of interest for this writer, who has lived on a sailboat for the last 15 years south of the border. Sanford has been active in San Diego sailing circles for some time. But his interest goes back a number of decades. He raced sailboats on Lake Minnetonka in Minnesota, where he grew up. And in 1973, he received the Bail Bond Award from the Wayzata Yacht Club on Lake Minnetonka for unspecified acts that demonstrated “the greatest love, spirit, and care for the Wayzata Yacht Club.”
Sunday, November 03, 2013
The Future of the California Stem Cell Agency: Cures, Priorities and Brain Drain
The California stem cell agency is nearing the end of its “normal”
life span, and the topic of its future comes up with some regularity
nowadays within the Golden State's stem cell community.
It is a tiny community that has benefited to the tune of $1.9 billion so far from the passage of Prop. 71, the ballot measure that created the agency nine years ago this month.
The latest public discussion of what UC Davis stem cell researcher Paul Knoepfler has dubbed “CIRM 2.0” came on Knoepfler's blog last week and a short time later on the agency's own blog. CIRM is the acronym for the California Institute for Regenerative Medicine, the formal name of the agency.
Predictably the most recent discussion, as generally occurs, emphasized the importance of the science and promise that it poses. Rarely heard, however, is whether the agency's efforts have been worth $6 billion (CIRM's projected cost including interest) and whether spending billions more over another decade ranks among the top ten priorities, for example, facing the state during the same period. That is the fundamental question facing CIRM if it is to seek additional public funding for its operations beyond 2017, when the cash for new grants will run out.
On his blog, Knoepfler cites four main reasons for the state to continue to support the agency at a high level. He says that it has “strongly boosted” the state's economy, made the state a global leader in stem cell research, created strong scientific momentum and, finally, that California faces a “potential harmful stem cell brain drain” should CIRM close its doors.
In a comment posted on Knoepfler's item, Jeanne Loring, head of the stem cell program at Scripps, said the future of CIRM inevitably arises in any conversation between any two stem cell researchers in California.
She said a “continued investment in CIRM will pay off enormously” for the state. She said,
Additionally, the California economy runs in the neighborhood of $2 trillion a year with approximately 19 million persons in the work force. Biotech, which accounts for a relatively picayune 200,000 employees or so in California, is a miniscule economic player. (See here and here.) Stem cell companies and research are even smaller. As for the $1.9 billion CIRM has awarded, it has gone to only 625 recipients, a handful of which are businesses or institutions.
If the agency is to be evaluated as an industry-development engine, the criteria are also considerably different than would be used to evaluate a research-funding organization. Such an industrial evaluation was resisted strongly by Robert Klein, the first chairman of the agency, when the California Stem Cell Report suggested it to him some years ago. Ironically, Klein likes to trot out CIRM's own, dubious economic study when it suits his purpose.
Production of stem cell “cures” or therapies is also unlikely to employ the hundreds of thousands of Californians needed to make a major economic impact. Actual production of any “cures” is likely to occur overseas for the usual business reasons and thus not provide massive amounts of jobs within the state. That said, the owners of successful stem cell companies could become extremely wealthy a la their cousins in the Silicon Valley.
California Gov. Jerry Brown, who is widely expected to seek re-election next year, has already identified two, long-term mega-projects that he believes are fundamental to the economic well-being of California – high speed rail and a massive water project. The cost of those two efforts is likely to run in the neighborhood of close to $100 billion, according to the most recent estimates. That is not to mention the financially starved University of California, state colleges and community colleges or even the youngsters who need to learn to read and write in the state's public schools. Adequate support of those institutions, which are critical to the state's economy, would require many more billions. Brown notably has not spoken publicly about his views on the value of the stem cell agency. His support would be needed for CIRM to acquire additional public dollars.
For the people of California, the question would be: How does stem cell research fit in with their perception of the needs of California, ranging from education to water to other priorities? At this point, the stem cell agency and its work are virtually unknown to the general public. The agency is working hard to improve its visibility and create an atmosphere conducive to generating more cash. But it is very much up in the air whether CIRM can successfully set the stage for infusion of more billions of public dollars.
It is a tiny community that has benefited to the tune of $1.9 billion so far from the passage of Prop. 71, the ballot measure that created the agency nine years ago this month.
The latest public discussion of what UC Davis stem cell researcher Paul Knoepfler has dubbed “CIRM 2.0” came on Knoepfler's blog last week and a short time later on the agency's own blog. CIRM is the acronym for the California Institute for Regenerative Medicine, the formal name of the agency.
Predictably the most recent discussion, as generally occurs, emphasized the importance of the science and promise that it poses. Rarely heard, however, is whether the agency's efforts have been worth $6 billion (CIRM's projected cost including interest) and whether spending billions more over another decade ranks among the top ten priorities, for example, facing the state during the same period. That is the fundamental question facing CIRM if it is to seek additional public funding for its operations beyond 2017, when the cash for new grants will run out.
On his blog, Knoepfler cites four main reasons for the state to continue to support the agency at a high level. He says that it has “strongly boosted” the state's economy, made the state a global leader in stem cell research, created strong scientific momentum and, finally, that California faces a “potential harmful stem cell brain drain” should CIRM close its doors.
In a comment posted on Knoepfler's item, Jeanne Loring, head of the stem cell program at Scripps, said the future of CIRM inevitably arises in any conversation between any two stem cell researchers in California.
She said a “continued investment in CIRM will pay off enormously” for the state. She said,
“CIRM has had the same effect on stem cell research that Genentech had on biotechnology; it showed that taking a chance on a focused investment in new technology could transform the future of medicine. Now, with CIRM’s focus on supporting partnerships of stem cell researchers with successful biotechnology companies, we have the best of both California-centric worlds: the power of technology applied to the abilities of stem cells. Such partnerships, especially in rapidly growing fields like genomics, will sustain progress beyond CIRM’s current reach.”There is little doubt that CIRM has had a positive impact on California. But the claims that it has “strongly boosted” the California economy are dubious. Such assertions are based on a report commissioned by the agency itself at a cost of $300,000. According to the RFP for the project, the recipient of the contract for the study was to execute "a vibrant and aggressive strategy to support the goals and initiatives of CIRM.” (See here and here.)
Additionally, the California economy runs in the neighborhood of $2 trillion a year with approximately 19 million persons in the work force. Biotech, which accounts for a relatively picayune 200,000 employees or so in California, is a miniscule economic player. (See here and here.) Stem cell companies and research are even smaller. As for the $1.9 billion CIRM has awarded, it has gone to only 625 recipients, a handful of which are businesses or institutions.
If the agency is to be evaluated as an industry-development engine, the criteria are also considerably different than would be used to evaluate a research-funding organization. Such an industrial evaluation was resisted strongly by Robert Klein, the first chairman of the agency, when the California Stem Cell Report suggested it to him some years ago. Ironically, Klein likes to trot out CIRM's own, dubious economic study when it suits his purpose.
Production of stem cell “cures” or therapies is also unlikely to employ the hundreds of thousands of Californians needed to make a major economic impact. Actual production of any “cures” is likely to occur overseas for the usual business reasons and thus not provide massive amounts of jobs within the state. That said, the owners of successful stem cell companies could become extremely wealthy a la their cousins in the Silicon Valley.
California Gov. Jerry Brown, who is widely expected to seek re-election next year, has already identified two, long-term mega-projects that he believes are fundamental to the economic well-being of California – high speed rail and a massive water project. The cost of those two efforts is likely to run in the neighborhood of close to $100 billion, according to the most recent estimates. That is not to mention the financially starved University of California, state colleges and community colleges or even the youngsters who need to learn to read and write in the state's public schools. Adequate support of those institutions, which are critical to the state's economy, would require many more billions. Brown notably has not spoken publicly about his views on the value of the stem cell agency. His support would be needed for CIRM to acquire additional public dollars.
For the people of California, the question would be: How does stem cell research fit in with their perception of the needs of California, ranging from education to water to other priorities? At this point, the stem cell agency and its work are virtually unknown to the general public. The agency is working hard to improve its visibility and create an atmosphere conducive to generating more cash. But it is very much up in the air whether CIRM can successfully set the stage for infusion of more billions of public dollars.
Wednesday, October 30, 2013
Italian Researcher Cattaneo Honored as 2013 Stem Cell Person of the Year
Elena Cattaneo, EuroStem Photo |
UC Davis researcher Paul Knoepfler announced his choice this morning on his blog, ipscell.com. Knoepfler began the contest last year and personally provides the $1,000 award. The first winner was Roman Reed, a California patient advocate.
In Knoepfler's announcement, he cited Cattaneo's work on neural stem cells, particularly in connection with possible therapies for Huntington's Disease. Cattaneo is director and co-founder of the Unistem, the center for stem cell research at the University of Milano, Italy, and has been appointed a senator for life in Italy.
Knoepfler also said,
"She is that rare stem cell scientist who goes well above and beyond the call of academic duty to act as an advocate as well."He said that she has "a track record of taking important public stands on key issues over the years."
Most recently, Knoepfler cited her efforts in connection with an organization called Stamina in Italy that was providing a stem cell therapy to large numbers of patients. The treatment this month was banned from testing in Italy after a panel of scientists determined it was excessively risky and not supported by evidence.
The decision followed a campaign by Cattaneo and others. Knoepfler wrote,
"She and a dozen fellow Italian scientists stood up to what was a flawed Italian governmental decision to allow Stamina to proceed with a gutsy letter. It takes courage to not only do your research, but also to take a stand against your own government's flawed decision and ultimately prevail. Her actions have helped to keep thousands of patients safer and protect the stem cell field."Her efforts and those of others inspired a play called "Staminalia: A Dream and a Trial," which premiered in Portugal in 2010. According to the EuroStemCell Web site, the play "goes beyond the science of stem cells to tell the story of a stem cell researcher and a mother who sees ethical and political limitations impacting not only into her scientific freedom, but also into her private life."
Monday, October 28, 2013
Flawed Research, Cursory Peer Review, Perverse Incentives
“Billions of dollars worth of wrong” is how the situation in
life science research is described in the Los Angeles Times this
week.
Strong words, but supported by findings from Amgen and Bayer HealthCare that may be well known in relatively tiny scientific circles but rarely heard in an outlet such as the Times. It is the largest circulation paper in California and says it reaches 8.6 million adults weekly in Los Angeles via print and the Internet -- not to mention its national pull.
The column on “verifiable facts” and science was written by Pulitzer Prize winner and author Michael Hiltzik.
Among other things, he cited a study by Amgen of Thousand Oaks, Ca., which examined 53 “landmark papers” in cancer research and blood biology. Only five could be proved valid, a shocking result, according to Amgen. Similar results were turned up by Bayer in Germany.
Hiltzik continued,
Hiltzik's main piece appeared on the Web yesterday. Today he had a follow-up dealing with the late Richard Feynman's “cargo cult science,” the term physicist used for published research that did not prove valid.
Hiltzik's bottom line?
Strong words, but supported by findings from Amgen and Bayer HealthCare that may be well known in relatively tiny scientific circles but rarely heard in an outlet such as the Times. It is the largest circulation paper in California and says it reaches 8.6 million adults weekly in Los Angeles via print and the Internet -- not to mention its national pull.
The column on “verifiable facts” and science was written by Pulitzer Prize winner and author Michael Hiltzik.
Among other things, he cited a study by Amgen of Thousand Oaks, Ca., which examined 53 “landmark papers” in cancer research and blood biology. Only five could be proved valid, a shocking result, according to Amgen. Similar results were turned up by Bayer in Germany.
Hiltzik continued,
"'The thing that should scare people is that so many of these important published studies turn out to be wrong when they're investigated further,' says Michael Eisen, a biologist at UC Berkeley and the Howard Hughes Medical Institute. The Economist recently estimated spending on biomedical R&D in industrialized countries at $59 billion a year. That's how much could be at risk from faulty fundamental research.Hiltzik goes on to discuss the flawed nature of peer review and “perverse incentives” in scientific research along with the new PubMed Commons project at the NIH, which Hiltzik said is aimed at substituting “continuing scrutiny” for “ a cursory, one-time peer review.”
"Eisen says the more important flaw in the publication model is that the drive to land a paper in a top journal — Nature and Science lead the list — encourages researchers to hype their results, especially in the life sciences. Peer review, in which a paper is checked out by eminent scientists before publication, isn't a safeguard. Eisen says the unpaid reviewers seldom have the time or inclination to examine a study enough to unearth errors or flaws.
"'The journals want the papers that make the sexiest claims,' he says. 'And scientists believe that the way you succeed is having splashy papers in Science or Nature — it's not bad for them if a paper turns out to be wrong, if it's gotten a lot of attention.'"
Hiltzik's main piece appeared on the Web yesterday. Today he had a follow-up dealing with the late Richard Feynman's “cargo cult science,” the term physicist used for published research that did not prove valid.
Hiltzik's bottom line?
"The demand for sexy results, combined with indifferent follow-up, means that billions of dollars in worldwide resources devoted to finding and developing remedies for the diseases that afflict us all is being thrown down a rathole. NIH and the rest of the scientific community are just now waking up to the realization that science has lost its way, and it may take years to get back on the right path."
For The Record
The California Stem Cell Report yesterday reported on an opening at the California stem cell agency for a high-level person to
work on charting a future sustainability course for the enterprise.
The new position redefines the role of the deputy to the chairman of the agency and renames the position. For the record, the post was held previously by Lynn Harwood, who left the agency when her husband took a job at Harvard, the agency said.
The new position redefines the role of the deputy to the chairman of the agency and renames the position. For the record, the post was held previously by Lynn Harwood, who left the agency when her husband took a job at Harvard, the agency said.
Sunday, October 27, 2013
California Stem Cell Agency Seeks New, Top Finance/Governance Aide
The $3 billion California stem cell agency is looking for a new,
high-level staff member to play a key role in developing a plan for
its future beyond 2017.
The posting for the position came last week, less than two months before a possible “strategic roadmap” for the agency is scheduled to be unveiled. CIRM, as the agency is known, will run out of cash for new grants in 2017.
The new hire will assist in “meeting the financing and sustainability goals” of the agency and will be a key aide to CIRM Chairman Jonathan Thomas, a Los Angeles bond financier. The job title -- – “deputy to chair for public finance and governance” – includes language new to CIRM i.e. “for public finance and governance.”
Salary for the position could run as high as $216,279, depending on the qualifications of the person.
CIRM is looking for someone with an MBA or other finance-related, advanced degree. The person should be knowledgeable not only about California government but have experience with biomedical research funding, grant-making and financial forecasting, among other things.
The previous deputy to the chair was Lynn Harwell, who left, the agency said, when her husband took at job at Harvard. Her formal title was “deputy to the chair, finance, policy and outreach.” The change in nomenclature obviously indicates a change in the focus of the job.
(Editor's note: The final paragraph of this item was added a day after the original item was posted.)
The posting for the position came last week, less than two months before a possible “strategic roadmap” for the agency is scheduled to be unveiled. CIRM, as the agency is known, will run out of cash for new grants in 2017.
The new hire will assist in “meeting the financing and sustainability goals” of the agency and will be a key aide to CIRM Chairman Jonathan Thomas, a Los Angeles bond financier. The job title -- – “deputy to chair for public finance and governance” – includes language new to CIRM i.e. “for public finance and governance.”
Salary for the position could run as high as $216,279, depending on the qualifications of the person.
CIRM is looking for someone with an MBA or other finance-related, advanced degree. The person should be knowledgeable not only about California government but have experience with biomedical research funding, grant-making and financial forecasting, among other things.
The previous deputy to the chair was Lynn Harwell, who left, the agency said, when her husband took at job at Harvard. Her formal title was “deputy to the chair, finance, policy and outreach.” The change in nomenclature obviously indicates a change in the focus of the job.
(Editor's note: The final paragraph of this item was added a day after the original item was posted.)
Thursday, October 24, 2013
Back in Romantic Old Mexico
For those of you who keep track of such things, the California
Stem Cell Report is now emanating from Mexico once again after
several years in Central America, including Panama.
More specifically, we are now in a marina just north of the Guatemalan-Mexican border near Tapachula, an area that grows many of the mangoes imported to the United States. Currently, however, they are out of the season and the soy bean harvest is coming to an end.
We have been living south of the border aboard a 39-foot sailboat, a cat-rigged ketch called Hopalong, since 1998. Of course there are trips back to the Old Country for visits with the grandchildren and to catch up on meetings of the California stem cell agency and related matters.
The plan is to travel farther north in Mexico this winter to enjoy the great food to be found in this country and to engage with its fine citizens. Beyond that, as cruising sailors say,
More specifically, we are now in a marina just north of the Guatemalan-Mexican border near Tapachula, an area that grows many of the mangoes imported to the United States. Currently, however, they are out of the season and the soy bean harvest is coming to an end.
We have been living south of the border aboard a 39-foot sailboat, a cat-rigged ketch called Hopalong, since 1998. Of course there are trips back to the Old Country for visits with the grandchildren and to catch up on meetings of the California stem cell agency and related matters.
The plan is to travel farther north in Mexico this winter to enjoy the great food to be found in this country and to engage with its fine citizens. Beyond that, as cruising sailors say,
“We have no plans, and we are sticking to them.”
Wednesday, October 23, 2013
Stanford Loses Star Stem Cell Researcher to Montana State University
Renee Reijo Pera, Stanford photo |
The news about Reijo Pera, whose research is recognized internationally, comes only one week after Alan Trounson announced he was leaving his post as the president of the $3 billion California stem cell agency to return to Australia.
Reijo Pera, 54, will become the new vice president for research, creativity and technology transfer at Montana State in Bozeman beginning Jan. 15. Currently director of Stanford's Center for Human Pluripotent Stem Cell Research and Education, Reijo Pera has won $24.4 million from the California stem cell agency in addition to her federally funded research.
She has been at Stanford since 2007 after leaving UC San Francisco. Prior to her 10 years at UC San Francisco, she was at MIT and the Whitehead Institute for Biomedical Research. (Her resume can be found here.)
Reporter Gale Schontzer of the Bozeman Daily Chronicle wrote anicely detailed story on Reijo Pera's appointment. Schonzter said that MSU research funding dropped 17 percent this year to $94 million, partly because of the loss of some researchers. She quoted a Montana spokesperson as saying that Reijo Pera “has amazing credentials that we think will continue to move our research forward.”
Schontzer reported that Reijo Pera's salary will be $200,000, “making her the third highest-paid administrator on the Bozeman campus.”
Reijo Pera also told the reporter that she “'absolutely loved' Stanford, but felt 'it's kind of time to do the next thing…. There is potential to do more at Montana State.'”
The news article also provided some interesting history on Reijo Pera. Schontzer said,
“In high school, Reijo Pera said she had no interest in science or college. But after graduating and working as a car dealership bookkeeper, she wanted more. She enrolled at the University of Wisconsin-Superior to major in business. A class in human genetics for non-majors changed her life.”Not mentioned in the Bozeman Chronicle story was a professional, Montana-Stanford linkage involving stem cell scientist Irv Weissman and Reijo Pera. In 2007, Weissman, director of the Stanford stem cell institute, hailed the hiring of Reijo Pera after playing a role in recruiting her.
Weissman has strong ties to Montana where he grew up and where he has a ranch.
Tuesday, October 22, 2013
Primer and Paean: Consumer Guide to Stem Cells
The article today on xconomy.com had some intriguing
elements: “secret online communities,” $100,000 payments to scam
artists and talk of New York Times best-sellers – not to mention
stem cells.
The article was about UC Davis researcher Paul Knoepfler and his new book, “Stem Cells: An Insider's Guide.” The story was written by Bernadette Tansey, a former San Francisco Chronicle reporter. Tansey said that Knoepfler's book “may never break into the New York Times best-seller ranks, but he still might make some publishing history.” She wrote,
The California Stem Cell Report carried an item last month on Knoepfler and his book. We agree that it is quite helpful and accessible, especially for persons seeking more information about undergoing stem cell treatments.
The article was about UC Davis researcher Paul Knoepfler and his new book, “Stem Cells: An Insider's Guide.” The story was written by Bernadette Tansey, a former San Francisco Chronicle reporter. Tansey said that Knoepfler's book “may never break into the New York Times best-seller ranks, but he still might make some publishing history.” She wrote,
“Knoepfler could be the only biology researcher ever to write a comprehensive consumer guide about the health care treatments being developed in his own field—complete with safety cautions.”Tansey summarized Knoepfler's book as “a scientific primer and a paean to the promise of stem cell research.” She also said the stem cell researcher sees
“a growing network of secret online communities, as well as overt advertisements, (that) have spurred US patients to pay fortunes out of pocket to ill-trained physicians, who perform experimental procedures backed by little or no evidence.”Knoepfler's greatest concern, Tansey said, “is for patients who have been lured by the false claims of dubious for-profit clinics to pay as much as $100,000 for unproven 'stem cell treatments.' These injections, he says, may actually consist of cells culled from pigs, cows, or sheep, and bear unknown risks such as contamination or immune system reactions.”
The California Stem Cell Report carried an item last month on Knoepfler and his book. We agree that it is quite helpful and accessible, especially for persons seeking more information about undergoing stem cell treatments.
Thursday, October 17, 2013
Semi-finalists Emerge for Stem Cell Person of the Year
The balloting for semi-finalists for the Stem Cell Person of the
Year is now complete, and two persons tied to the California stem
cell agency are among them.
Twelve persons in all made the cut with scientist Robert Lanza of Advanced Cell Technology receiving the most votes. Jeff Sheehy, a member of the governing board of the stem cell agency and an AIDS activist, and Pat Olson, executive scientific director of the agency, are also among the semi-finalists.
Now, however, it is not a matter of who receives the most support. Only one vote counts. And that belongs to Paul Knoepfler, the UC Davis stem cell researcher who originated the Person of the Year award last year. He runs it and personally awards the winner $1,000.
Knoepfler said he expects to announce the winner in a week or so. The names of all those being considered can be found on in this item on Knoepfler's blog, ipscell.com.
Twelve persons in all made the cut with scientist Robert Lanza of Advanced Cell Technology receiving the most votes. Jeff Sheehy, a member of the governing board of the stem cell agency and an AIDS activist, and Pat Olson, executive scientific director of the agency, are also among the semi-finalists.
Now, however, it is not a matter of who receives the most support. Only one vote counts. And that belongs to Paul Knoepfler, the UC Davis stem cell researcher who originated the Person of the Year award last year. He runs it and personally awards the winner $1,000.
Knoepfler said he expects to announce the winner in a week or so. The names of all those being considered can be found on in this item on Knoepfler's blog, ipscell.com.
Minor News Coverage of Trounson Resignation; More Likely Later Today
So far today news coverage has been light of the resignation of
Alan Trounson as president of the $3 billion California stem cell
agency.
In addition to the California Stem Cell Report, which was first with the news last night, Ron Leuty of the San Francisco Business Times and scientist/blogger Paul Knoepfler carried items.
(See here for the main story on the California Stem Cell Report and here for an email from Trounson. See here for the agency's press release at 6 p.m. PDT yesterday.)
Leuty's report was a straight-forward news account, but Knoepfler, a stem cell researcher at UC Davis, weighed in with a brief analysis. Knoepfler wrote,
The evaluation subcommittee of the governing board of the agency has also scheduled a meeting for this morning concerning the board's evaluation of Trounson. We have queried the agency about whether that meeting will go on as scheduled.
In addition to the California Stem Cell Report, which was first with the news last night, Ron Leuty of the San Francisco Business Times and scientist/blogger Paul Knoepfler carried items.
(See here for the main story on the California Stem Cell Report and here for an email from Trounson. See here for the agency's press release at 6 p.m. PDT yesterday.)
Leuty's report was a straight-forward news account, but Knoepfler, a stem cell researcher at UC Davis, weighed in with a brief analysis. Knoepfler wrote,
“A new CIRM president will find herself or himself tasked with not only running the agency, but also leading the agency to what will likely be a new kind of future. The new president will need vision as to what CIRM will do once the funding from Prop. 71 runs out in a few years and they’ll also need the know-how and management skills to make that vision into a reality.
“There aren’t that many people in the entire world who have the chops to take that on and be successful.”Later today, more stories are likely to be seen as other media catch up with the events.
The evaluation subcommittee of the governing board of the agency has also scheduled a meeting for this morning concerning the board's evaluation of Trounson. We have queried the agency about whether that meeting will go on as scheduled.
Wednesday, October 16, 2013
Text of Trounson Letter Re Resignation
Last week the California Stem Cell Report emailed Alan Trounson
concerning his continued tenure as president of the California stem
cell agency. (See here for the earlier main story on his resignation late today.) The query noted that he had missed some meetings of the
governing board of the agency and had been away for three months in
Australia earlier this year, among other things. Here is the text of
his response.
“I missed the May and October Board Meetings. In May, I was completing as Chair of the Scientific Advisory Board review of the Max Planck Institute for Molecular Biomedicine, Muenster, Germany. In October, I was invited along with 50 other leading scientists from around the world to speak and participate in the Nature Medicine Conference on Stem Cells and Regenerative Medicine in Hanover – Issues to Solve for Biology and Medical Applications. This was a critical global meeting for CIRM to be represented at. On both occasions I requested the Board meeting be moved to enable me to be there but this was not possible. In both cases the Chair agreed I should attend the activities in Germany.
“Between Christmas and the end of February, I was in Australia but worked for CIRM for 50% of this time, excluding holidays, on reports, meetings (teleconferences, SKYPE conferences), articles for scientific journals for CIRM and meetings with collaborating partners and grantees there. I returned to San Francisco in mid-February for the Genomics GWG Review. I returned to Australia for my daughter’s wedding and then returned to San Francisco at the end of February. Dr Ellen Feigal and I were in continual communications while I was away and CIRM worked very smoothly and efficiently under her management and my guidance.
“When I was asked to become President, by Governor Schwarzenegger and previous Chairman Bob Klein, I made a commitment to them for CIRM. I did that with the understanding that my partner Karin and our young son could be with me in California. They did move here for 3 years, but it turned out to be impossible for Karin to continue her career in women’s health research at a Californian university. For her to work at any California institution would have created too many conflict issues, either because of the rules or because of 'appearance' concerns. Karin and our young son moved back to Australia, and I moved to an apartment 2 blocks from CIRM. I work seven days a week for CIRM in the absence of my family. I have a 12-year old son who misses me terribly for the last 2.5 years we have been separated (as do the other 3 older children). I have sacrificed considerable personal family rewards to continue to commit to driving CIRMs vision.
“The whole 'evaluation of the president' process with the board has always seemed (to me) to drag on forever with meeting after meeting. I have not attended any of this year’s meetings, but my dialog with them has been about evaluating whether my role at CIRM could be modified in some way to accommodate my families needs. Duane Roth was the key person for me in those discussions, as he was on so many issues. It has taken some time to regroup after his untimely death and enable this to move forward again.”
CIRM Press Release on Trounson Departure
Here is the news release today from the California stem Cell agency on Trounson's resignation.
CIRM President Alan Trounson To Step Down
October 16, 2013
San Francisco, CA – Alan Trounson, PhD, has announced he is going to step down as President of the stem cell agency, the California Institute for Regenerative Medicine (CIRM), in order to spend more time with his family in Australia.
Dr. Trounson says the agency’s governing Board, the Independent Citizens Oversight Committee (ICOC), has asked him, and he has agreed, to remain as President, while the agency begins the search for a new President.
The agency is also discussing with Dr. Trounson the possibility of him remaining affiliated with the agency in a role to be determined.
“We have accelerated the development of regenerative medicine, and I would love to continue at CIRM as these advancements begin making a difference to patients with debilitating injuries and disease. But the agency needs a full-time President and I need to spend more time with my family. The two needs are incompatible, so it is necessary for me to step down as President. This was a very difficult decision to make,” says Dr. Trounson. “I have loved working at CIRM and being part of something truly pioneering – a revolution in stem cell science and medicine – but ultimately it came down to a choice between CIRM and a life including my family.”
“Alan has been a remarkable leader of the agency for almost six years,” says Jonathan Thomas, PhD, JD, Chair of the Board. “He has led us through some challenging times, been the driving force behind some truly innovative ideas – such as the Bridges and Creativity Training Programs, the Alpha Clinic model for delivering new therapies to patients, a stem cell genomics program and an iPS cell bank for interrogating the cause and developing new treatments for really serious and complex diseases. He has helped establish us as a world leader in the field of stem cell research. We are truly grateful for his vision, his expertise and his leadership. He has created a legacy which he can be proud of.”
Dr. Trounson joined CIRM in late 2007 after serving as Professor of Stem Cell Sciences and Founding Director of the Monash Immunology and Stem Cell Laboratories at Monash University in Melbourne, Australia. He also founded the National Biotechnology Centre of Excellence – more commonly called the ‘Australian Stem Cell Centre’, co-founded the Monash Institute for Reproduction and Development – and was a pioneer in the development of human in vitro fertilization (IVF).
"Since joining CIRM in 2007, Alan has helped transform not only this agency but the entire field of stem cell research," says Sherry Lansing, Cancer Patient Advocate and longtime Chair of the Board's Governance Subcommittee. "Alan has instilled a sense of urgency in our core mission -- funding research that is leading to faster clinical trials of treatments for deadly diseases."
Jeff Sheehy, another longtime Board member and a Patient Advocate for HIV says; "Alan has been an irresistible force in moving stem cell therapies into the clinic and, as a patient advocate, I am deeply grateful to him for his relentless determination. One of the key features of his extraordinary leadership over the last six years has been his ability to achieve one of the seminal visions embedded in Proposition 71, the seamless integration of patients, industry and researchers into a harmonious, synergistic union. We are much, much closer to cures, thanks to his efforts."
“It’s been an amazing time, working with some of the most dedicated people and inspirational individuals,” says Dr. Trounson. “I feel both fortunate and honored to have been part of something that is transforming the face of medicine, and part of an organization that is helping lead the world in that transformation. I have been privileged to work with some very special colleagues at CIRM and I know their expertise, professionalism and dedication will be a tremendous resource for my successor.”
About CIRM: CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research.
Trounson Resigns as President of $3 Billion California Stem Cell Agency
Trounson, an internationally known pioneer in IVF research, said he was resigning so that he could rejoin his family in Australia, where he has spent most of his personal and professional life.
Trounson's wife and youngest son moved back to Australia from California about three years ago. In a news release from the stem cell agency, Trounson said,
“(T)he agency needs a full-time president, and I need to spend more time with my family. The two needs are incompatible, so it is necessary for me to step down as president."In an email to the California Stem Cell Report, Trounson said,
“I have a 12-year old son who misses me terribly for the last 2.5 years we have been separated (as do the other 3 older children). I have sacrificed considerable personal family rewards to continue to commit to driving CIRM's vision.”Trounson joined the California Institute of Regenerative Medicine (CIRM), as the agency is formally known, in late 2007. He was personally recruited by Robert Klein, the first chairman of the stem cell agency, during a trip to Australia. Trounson also said today that then Gov. Schwarzenegger asked him to serve.
During Trounson's tenure, the agency's portfolio has soared from $283 million and 156 awards to its current $1.9 billion and 570 awards. It has about $600 million remaining in uncommitted funds.
Trounson's departure comes at a critical moment for the agency, which is trying to find a way to continue with major operations beyond 2017, when the money for new grants will run out. It is also pressing hard to commercialize stem cell research, the primary goal of Prop. 71, the ballot initiative that created the agency in 2017.
CIRM said Trounson has agreed to stay on as the agency begins its search for a new president. The agency said it is discussing the possibility of some sort continued affiliation for Trounson with the stem cell effort.
Members of the agency's governing board had high praise for Trounson today. Jonathan Thomas, chairman of the board, said in the CIRM news release that Trounson helped established the agency as a “world leader.”
“He has led us through some challenging times, been the driving force behind some truly innovative ideas – such as the Bridges and Creativity Training Programs, the Alpha Clinic model for delivering new therapies to patients, a stem cell genomics program and an iPS cell bank for interrogating the cause and developing new treatments for really serious and complex diseases.”Sherry Lansing, chair of the directors' Governance Subcommittee and a former Hollywood studio head and former chair of the University of California regents, described Trounson as an “irresistible force.” She said,
“We are much, much closer to cures, thanks to his efforts."Trounson's years at CIRM were not without controversy. In 2009, Marie Csete left the agency as its chief scientific officer. She told the journal Nature her advice was “not respected” at the agency.
This year, news surfaced on the California Stem Cell Report concerning Trounson's conduct in connection with a $21,630 gift from Klein to the agency along with a conflict-of-interest case involving a scientific grant reviewer who Trounson recruited.
The stem cell agency has had difficulties recruiting candidates for president in the past -- for among other reasons -- the early legal challenges and because of its dual executive arrangement legally dictated by Prop. 71. The dual CEO situation means that the chairman and president have overlapping responsibilities. CIRM is also an unusual mix, at least for a state agency, of science, academia, business and politics. Previous presidential searches also have become enmeshed in an internal debate over whether the president should be a big name scientist or more of an administrator.
The agency currently has new challenges that include creation of a“strategic road map” for its future and tough decisions on which projects to back for commercialization – not to mention the agency's short life span if it cannot find new financing.
In response to a query, Kevin McCormack, a spokesman for the agency said no severance is being provided to Trounson. The spokesman said Trounson's current salary is $490,008, the same as when he joined the agency.
You can find the CIRM press release here. Here is the text of Trounson's email to the California Stem Cell Report.
Tuesday, October 15, 2013
California Stem Cell Debt: Refinancing $146 Million
The state of California is planning a $2.2 billion bond sale next week with about $146 million of it going to refinance debt run
up by the California stem cell agency.
The new, long-term borrowing will pay off short-term debt used for stem cell research over the last two years.
The $3 billion agency was set up to subsist on money borrowed long-term by the state with general obligation bonds. The ballot initiative that created the agency, Prop. 71 of 2004, authorized the bonds. Interest on the bonds roughly doubles the cost of the research.
In 2011, Gov. Jerry Brown sounded an alarm about California's burgeoning wall of debt and sales of bonds were cut back. The agency maintained its operations through the short-term borrowing (commercial paper).
Authorization for the bonds ends in 2017 and the agency is scheduled to run out of cash for new grants that year as well. The agency is attempting to devise some sort of public-private mechanism to generate funds after 2017.
A financial statement prepared by the state treasurer's office for the Oct. 22 bond sale said that $1.2 billion in stem cell bonds was outstanding and $1.6 billion was unissued as of Sept. 1.
Individuals will have an opportunity this month to buy the bonds during an early order period. But they will not enjoy the benefits provided by non-taxable bonds.
All of the stem cell bonds are taxable, as opposed to many state bonds that are not. During the 2004 ballot campaign for Prop. 71, the public was led to believe that the agency would be financed with non-taxable bonds, which would have meant much lower borrowing costs for the state to the tune of hundreds of millions of dollars.
In 2007, Bernadette Tansey, then of the San Francisco Chronicle, reported that Robert Klein, head of the Prop. 71 campaign and first chairman of the stem cell agency, knew that taxable bonds were likely to be required but did not disclose that fact to the public.
The agency has awarded $1.9 billion and has about $600 million in uncommitted funds. The remainder of the $3 billion is going for administrative expenses over the life of the agency. The agency said last week it had $61.4 million on hand as of Sept. 30.
Earlier this month, Michael Marois of Bloomberg News reported,
The new, long-term borrowing will pay off short-term debt used for stem cell research over the last two years.
The $3 billion agency was set up to subsist on money borrowed long-term by the state with general obligation bonds. The ballot initiative that created the agency, Prop. 71 of 2004, authorized the bonds. Interest on the bonds roughly doubles the cost of the research.
In 2011, Gov. Jerry Brown sounded an alarm about California's burgeoning wall of debt and sales of bonds were cut back. The agency maintained its operations through the short-term borrowing (commercial paper).
Authorization for the bonds ends in 2017 and the agency is scheduled to run out of cash for new grants that year as well. The agency is attempting to devise some sort of public-private mechanism to generate funds after 2017.
A financial statement prepared by the state treasurer's office for the Oct. 22 bond sale said that $1.2 billion in stem cell bonds was outstanding and $1.6 billion was unissued as of Sept. 1.
Individuals will have an opportunity this month to buy the bonds during an early order period. But they will not enjoy the benefits provided by non-taxable bonds.
All of the stem cell bonds are taxable, as opposed to many state bonds that are not. During the 2004 ballot campaign for Prop. 71, the public was led to believe that the agency would be financed with non-taxable bonds, which would have meant much lower borrowing costs for the state to the tune of hundreds of millions of dollars.
In 2007, Bernadette Tansey, then of the San Francisco Chronicle, reported that Robert Klein, head of the Prop. 71 campaign and first chairman of the stem cell agency, knew that taxable bonds were likely to be required but did not disclose that fact to the public.
The agency has awarded $1.9 billion and has about $600 million in uncommitted funds. The remainder of the $3 billion is going for administrative expenses over the life of the agency. The agency said last week it had $61.4 million on hand as of Sept. 30.
Earlier this month, Michael Marois of Bloomberg News reported,
"(State Treasurer Bill) Lockyer has said he plans to offer an estimated $12.5 billion of debt in the next 18 months. As of Sept. 1, California had $79.4 billion in long-term bonds outstanding, out of $147.8 billion authorized by voters, according to Lockyer’s website.”
Sunday, October 13, 2013
Final Voting This Week for Stem Cell Person of the Year
Thousands of votes have been tallied so far in the balloting for the
Knoepfler Lab's Stem Cell Person of the Year as this week's deadline
fast approaches.
The cutoff date is this Wednesday at 11:59 p.m. PDT (0659 Greenwich Mean Time). For those of you who aren't up to speed on this event, it is backed by Paul Knoepfler, a UC Davis stem cell researcher and blogger who initiated the award in 2012. He personally coughs up $1,000 for the winner. He also decides who the ultimate winner will be. This week's ballot is to decide the final 12 out of a field of 30 nominees.
We asked Paul to give us an update today (Sunday) on the state of the balloting. About midday, he sent along the following.
As we all know, science is a collaborative enterprise. Making good things happen is the business of more than one person. And it is fair to say that the staff of the California stem cell agency has been an important key in maintaining the vitality of the stem cell field research as it has traversed some rocky roads since 2004.
Rules for voting can be found here.
The cutoff date is this Wednesday at 11:59 p.m. PDT (0659 Greenwich Mean Time). For those of you who aren't up to speed on this event, it is backed by Paul Knoepfler, a UC Davis stem cell researcher and blogger who initiated the award in 2012. He personally coughs up $1,000 for the winner. He also decides who the ultimate winner will be. This week's ballot is to decide the final 12 out of a field of 30 nominees.
We asked Paul to give us an update today (Sunday) on the state of the balloting. About midday, he sent along the following.
“We now stand at 3,300 valid votes with 3 1/2 days of voting left for picking the top 12 finalists.
“ I've added a countdown timer clock to the deadline at the top of the blog. That's kind of fun.
“Robert Lanza and Chris Centeno are vying back and forth for the top vote spot.
“Patient advocate Ted Harada is steady at 3rd place and Don Reed at 4th place. Followed now by the Pope at 5th place.
“Italian scientist and advocate Elena Cattaneo is next followed by Jeff Sheehy(a governing board member) of CIRM (the California stem cell agency) and bioethicist Leigh Turner.
“Then Sabrina Cohen, advocate, and Pat Olson (executive scientific director) of CIRM.
“The last two spots at the moment in the top 12 are Mitalipov, who did human therapeutic cloning this year, and Masayo Takahashi, running the first iPS cell human clinical study.
“About 1,000 votes in total had to be removed because a few voters broke the rules of 4 votes per day.
“When the time is up, the top 12 vote getters will move on as finalists.”Our recommendation: Vote for Pat Olson, who has served the stem cell agency since 2006. She is a fine representative of the staff of the agency, which has labored mightily this year and over the last nine years, pumping out about $300 million a year for stem cell research. Thousands of applications have been evaluated, and 570 awards handed out with many more to come – not to mention the critical monitoring of the publicly funded grant work.
As we all know, science is a collaborative enterprise. Making good things happen is the business of more than one person. And it is fair to say that the staff of the California stem cell agency has been an important key in maintaining the vitality of the stem cell field research as it has traversed some rocky roads since 2004.
Rules for voting can be found here.
Subscribe to:
Posts (Atom)